prokidney (nasdaq: prok), a pioneer in the treatment of ckd through innovations in cellular therapy, was founded in 2015 after a decade of research. prokidney’s lead product candidate, react™ (renal autologous cell therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of ckd, but in some cases potentially drive meaningful improvement in kidney function. late-stage ckd, stage 3b - 4, is a key target for react™ therapy. react™ has received regenerative medicine advanced therapy (rmat) designation, as well as fda and ema guidance, supporting its ongoing phase 3 clinical program, which launched in january 2022. for more information, visit www.prokidney.com.
Company profile
Ticker
PROK, PROK-BIVA, PROK-MM
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Social Capital Suvretta Holdings Corp. III
SEC CIK
Corporate docs
Subsidiaries
ProKidney Corp. GP Limited • ProKidney LP • ProKidney, LLC • ProKidney Acquisition Company, LLC ...
IRS number
981586514
PROK stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
25 Mar 24
S-8
Registration of securities for employees
22 Mar 24
8-K
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K/A
Departure of Directors or Certain Officers
18 Mar 24
8-K/A
Departure of Directors or Certain Officers
18 Mar 24
8-K
Departure of Directors or Certain Officers
12 Feb 24
8-K
Regulation FD Disclosure
26 Jan 24
Transcripts
Latest ownership filings
4
Darin J. Weber
23 Apr 24
144
Notice of proposed sale of securities
18 Apr 24
4
Darin J. Weber
17 Apr 24
4
Darin J. Weber
16 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
144
Notice of proposed sale of securities
12 Apr 24
4
Ulrich Peter Alfred Ernst
2 Apr 24
3
Ulrich Peter Alfred Ernst
2 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
James Coulston
5 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 191.39 mm | 191.39 mm | 191.39 mm | 191.39 mm | 191.39 mm | 191.39 mm |
Cash burn (monthly) | 17.39 mm | 26.24 mm | 15.54 mm | 13.13 mm | 7.93 mm | 6.70 mm |
Cash used (since last report) | 122.13 mm | 184.34 mm | 109.14 mm | 92.22 mm | 55.67 mm | 47.09 mm |
Cash remaining | 69.26 mm | 7.05 mm | 82.25 mm | 99.17 mm | 135.72 mm | 144.30 mm |
Runway (months of cash) | 4.0 | 0.3 | 5.3 | 7.6 | 17.1 | 21.5 |
Institutional ownership, Q3 2023
90.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 71 |
Opened positions | 17 |
Closed positions | 6 |
Increased positions | 15 |
Reduced positions | 27 |
13F shares | Current |
---|---|
Total value | 186.46 bn |
Total shares | 209.88 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Tolerantia | 94.68 mm | $817.07 mm |
Carso, S.A. de C.V. Inversora | 63.12 mm | $544.71 mm |
Palihapitiya Chamath | 11.57 mm | $56.13 mm |
Social Capital | 11.57 mm | $53.00 bn |
MS Morgan Stanley | 10.29 mm | $47.11 bn |
Suvretta Capital Management | 3.87 mm | $17.71 bn |
Vanguard | 3.29 mm | $15.08 bn |
BLK Blackrock | 2.81 mm | $12.88 bn |
Bleichroeder | 2.00 mm | $9.16 bn |
BAC Bank Of America | 1.42 mm | $6.51 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Apr 24 | Darin J. Weber | Class A Ordinary Shares | Sell | Dispose S | No | Yes | 2.5134 | 16,438 | 41.32 k | 155,194 |
18 Apr 24 | Darin J. Weber | Class A Ordinary Shares | Sell | Dispose S | No | Yes | 2.535 | 800 | 2.03 k | 171,632 |
16 Apr 24 | Darin J. Weber | Class A Ordinary Shares | Sell | Dispose S | No | Yes | 2.5 | 17,238 | 43.10 k | 172,432 |
12 Apr 24 | Darin J. Weber | Class A Ordinary Shares | Sell | Dispose S | No | Yes | 1.73 | 84,103 | 145.50 k | 189,670 |
1 Apr 24 | Ulrich Peter Alfred Ernst | Employee stock option Class A Ordinary Shares | Grant | Acquire A | No | No | 1.6 | 335,000 | 536.00 k | 335,000 |
1 Apr 24 | Darin J. Weber | Class A Ordinary Shares | Sell | Dispose S | No | Yes | 1.69 | 300 | 507.00 | 273,773 |
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
17 Apr 24
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
15 Apr 24
12 Health Care Stocks Moving In Monday's Intraday Session
15 Apr 24
12 Health Care Stocks Moving In Friday's After-Market Session
8 Mar 24
Morgan Stanley Assumes ProKidney at Equal-Weight, Announces Price Target of $3
7 Mar 24